Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

3.234 +0.374 (+13.08%)
Streaming Delayed Price Updated: 9:40 AM EDT, Jun 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Chromadex Corp CS

< Previous 1 2 3 4 Next >
ChromaDex to Participate in the LD Micro Invitational XIII
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports First Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
From ChromaDex Corpor
Via Business Wire
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
From ChromaDex Corporation
Via Business Wire
A Letter from the ChromaDex Chief Executive Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
From ChromaDex Corporation
Via Business Wire
ChromaDex Named Brianna Gerber Chief Financial Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
From ChromaDex Corporation
Via Business Wire
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
From ChromaDex Corporation
Via Business Wire
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
From ChromaDex Corporation
Via Business Wire
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
From ChromaDex Corporation
Via Business Wire
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
From ChromaDex Corporation
Via Business Wire
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.